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Abstract
Rift Valley fever virus (RVFV) is a veterinary and human pathogen and is an agent of bioterrorism concern. Currently, RVFV treatment is limited to supportive care, so new drugs to
control RVFV infection are urgently needed. RVFV is a member of the order Bunyavirales,
whose replication depends on the enzymatic activity of the viral L protein. Screening for
RVFV inhibitors among compounds with divalent cation-coordinating motifs similar to
known viral nuclease inhibitors identified 47 novel RVFV inhibitors with selective indexes
from 1.1–103 and 50% effective concentrations of 1.2–56 μM in Vero cells, primarily αHydroxytropolones and N-Hydroxypyridinediones. Inhibitor activity and selective index was
validated in the human cell line A549. To evaluate specificity, select compounds were tested
against a second Bunyavirus, La Crosse Virus (LACV), and the flavivirus Zika (ZIKV).
These data indicate that the α-Hydroxytropolone and N-Hydroxypyridinedione chemotypes
should be investigated in the future to determine their mechanism(s) of action allowing further development as therapeutics for RVFV and LACV, and these chemotypes should be
evaluated for activity against related pathogens, including Hantaan virus, severe fever with
thrombocytopenia syndrome virus, Crimean-Congo hemorrhagic fever virus.

Data Availability Statement: All relevant data are
within the paper and its Supporting information
files.

1. Introduction
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Small compound efficacy against Bunyavirales

health: Rift Valley fever virus (RVFV), La Crosse virus (LACV), Hantaan virus, severe fever
with thrombocytopenia virus (SFTSV), and Crimean-Congo hemorrhagic fever virus
(CCHFV) [1, 2]. RVFV is an arbovirus transmitted to animals by mosquito vectors. It is traditionally endemic in eastern and southern Africa but has recently expanded its range throughout sub-Saharan Africa and parts of the Middle East. RVFV is a serious veterinary pathogen,
causing Rift Valley fever in domestic animals including cattle, horses, sheep, goats, and camels.
Rift Valley fever is characterized by fever, hemorrhage, diarrhea, death, and nearly complete
spontaneous abortions in infected animals. Veterinary outbreaks of RVFV infections can
reach epidemic proportions, particularly in rainy years [3, 4]. Often, RVFV has a severe economic impact in regions with many affected herds.
Humans can also be infected by RVFV via contact with infected animal body fluids or tissues, by breathing droplets contaminated with RVFV, or less frequently via mosquito bites;
with human to human transmission of RVFV being rare [2]. Most human infections are either
asymptomatic or cause mild fever with hepatic involvement. However, 8–10% of infections
become severe, where symptoms can include lesions to the eye which cause blindness in 50%
of ocular cases, encephalitis, gastrointestinal dysfunction, jaundice, joint/muscle pain, hemorrhagic fever, disorientation/hallucination, and partial paralysis ([5], Reviewed in [2]). Hemorrhagic fever is rare (~1% of cases) but has a ~50% fatality rate in cases where it occurs. Human
RVFV infections can be diagnosed by ELISA or RT-PCR assays, but treatment is limited to
supportive care [2]. Currently, there is a live-attenuated veterinary vaccine approved for RVFV
(MP12), which has undergone a phase I clinical trial for use in humans (NCT00415051).
In addition to RVFV, LACV is an arbovirus found throughout the midwestern United
States, with childhood infections commonly underdiagnosed due to a lack of available diagnostics and therapeutics [6, 7]. Currently there are 50–150 cases of neuroinvasive disease
reported annually [8]. Since 2011, LACV has continued to spread beyond the Midwest and
into northeastern, mid-Atlantic and southern states, resulting in 700 cases of neuroinvasive
disease since 2011 [9].
All viruses of the order Bunyavirales replicate within the cytoplasm, facilitated by the L protein which is comprised of the RNA-dependent RNA polymerase (RdRp), cap binding domain
and viral endonuclease. These activities can make Bunyavirales a target for both direct acting
antivirals as well as host direct antivirals [10–12]. The virally encoded enzymes requires either
Mg++ or Mn++ ions for catalysis and hence viral replication [1, 13]. This is analogous to the
Mg++-binding motif of the Influenza Virus PA cap-snatching endonuclease [14] and bears significant similarity to the D‥E‥D‥D or D‥D‥E motifs found in ribonucleases H and viral integrases [15]. Inhibiting viral enzymatic function by altering Mg++ or Mn++ ions can block viral
replication, as has been shown for the HIV integrase [16], the HIV ribonuclease H [17], the
Hepatitis B Virus (HBV) ribonuclease H [18], and the influenza virus cap-snatching enzyme
[19, 20]. The most common mode of inhibition is for small molecules to chelate the Mg++ ions
in viral enzymatic active sites, with specificity and affinity modulated by additional contacts
between the inhibitors and the enzymes [21–23], and sometimes also by contacts with the
nucleic acid substrate [24]. This metal-chelating mechanism is used by the HIV integrase
inhibitors Bictegravir [25], Dolutegravir [26, 27], Elvitegravir [28], and Raltegravir [28], and
the Influenza Virus PA cap-snatching inhibitor Baloxavir marboxil [29]. The US Food and
Drug Administration has approved 62 drugs that act by coordinating active-site cations in
metalloenzymes as of 2017 [30], making active site metal ion chelation a well-established drug
mechanism.
In these studies, we hypothesized that metal chelating compounds similar to inhibitors of
the HIV and HBV ribonucleases H, the HIV integrase, and the Influenza Virus PA endonuclease would inhibit RVFV and LACV replication. This hypothesis is based on i) the inhibitory
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mechanism employed by metal chelating compounds against metalloenzymes, ii) the essential
nature of the L protein enzymatic function for viral replication [31], iii) the structural similarities of Mg++-dependent viral endoribonucleases, even between the Phenuiviridae and Peribunyaviridae families [15, 31, 32], and iv) the successes in developing drugs for HIV and
Influenza virus that act by chelating the catalytic Mg++ ions. In order to evaluate metal chelating compounds, we developed and validated assays to quantify live virus growth in the presence of potential antiviral compounds. Using these assays, we screened 397 compounds to
identify chemotypes with antiviral potential in both non-human primate and human cell lines.
We then further identified compounds which had activity against the Phlebovirus RVFV and
the closely related Orthobunyavirus, LACV. To determine specificity against bunyaviruses versus RNA viruses, we measured the in vitro efficacy of the best compounds against the positive
strand RNA flavivirus, Zika. Additionally, we developed live virus assays to quantify antiviral
compound activity validated these assays using known antivirals.

2. Materials and methods
2.1. Compound acquisition and synthesis
Commercially acquired compounds are indicated by the vendor’s name and catalog number
in S1 Table. Thiotropolones (TTP) compounds were synthesized as described in [33]. αHydroxytropolones (αHT) compounds were synthesized as described in [34]. For 265, 308,
and 311 see [35]. For 169 and 362 see [36]. For 385, 694, 696, 698, 700, 702, 704, 703, 838, and
840 see [37]. For 321, 336, 358, and 359 see [38]. For 388, 389, 390 and 539 see [39]. For 330
and 331 see [40]. For 113, 118 and 120 see [41]. For 260 see [42]. For 111 see [34]. For 335 see
[43].
The novel N-hydroxypyridinediones (HPD) compounds were synthesized following a
three-step synthetic procedure (S1 Data, Scheme 1). The key structure 5-acetyl-1-(benzyloxy)6-hydroxy-4-methylpyridin-2(1H)-one (ZEV1) was synthesized with an improved yield of
75% by refluxing a mixture of O-benzyl hydroxylamine (1 eq) and diketene (2 eq) in the presence of triethylamine (1 eq) in dry toluene. Subsequently, the benzyl group was cleaved by catalytic hydrogenation over 10% palladium on carbon to afford the target compound ZEV2
almost quantitatively. 5-Acetyl-1,6-dihydroxy-4-methylpyridin-2(1H)-one (ZEV2) was coupled with the appropriate substituted aniline using sulfuric acid as catalyst in absolute ethanol
at reflux. The desired compounds were obtained in good yields ranging from 60% to 70%,
with the only exception being 668 (ZEV-V5) which was isolated in an overall yield of 25%.
HPD compounds not published previously include 515–518, 668 and 670; preparation procedures and characterization data of compounds are in S1 Data. Nucleoside analogues ribavirin
and β-D-N4-Hydroxycytidine N4-Hydroxycytidine were purchased from Cayman Chemical.
Compounds were diluted to 10 mM in DMSO and stored in single-use aliquots in opaque
tubes at -20 ˚C.

2.2. Cells and viruses
RVFV strains MP-12 and ZH501, as well as LACV strain original (BEI NR-540) were passaged
in Vero E6 cells (ATCC1 CRL-1586™) before clarification by centrifugation at 3,000 rpm for
30 minutes and stored at -80˚C until further use. RVFV isolates were a kind gift of Drs. M. Buller (Saint Louis University) and A. Hise (Case Western Reserve University). MP-12 is a BSL-2
vaccine strain of RVFV and is not classified as a select agent allowing easier assay development.
The ZIKV strain, PRVABC59 was a kind gift of Robert Lanciotti (CDC). Virus inhibition
assays and toxicity assays, described below, were completed in both Vero E6 and A549 cells
(ATCC CCL-185). Unless otherwise specified, all cells were cultured in Dulbecco’s Modified
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Eagle Medium (Sigma- D5796-500ML) containing 1% HEPES (Sigma- H3537-100ML) and
5% FBS (Sigma- F0926) at 37˚C, 5% CO2. Studies with infectious RVFV-ZH501 viruses were
approved by the SLU IBC and were conducted in our select agent registered A/BSL-3
laboratory.

2.3. Focus Forming Assay (FFA)
FFAs are used to quantify infectious virus and are the basis for the antiviral compound inhibition assay. Briefly, 100μL of Vero E6 cells at a concentration of 3x105 cells/ml were plated in a
96-well flat bottom plate resulting in a confluency of 90–95% the day prior to the assay. To
quantify viral stocks, ten-fold serial dilutions of virus supernatants were then made in a
96-well round bottom plate containing 5% DMEM media before being added to the Vero cell
monolayer and allowed to adsorb for one hour in an incubator with 37˚C, 5% CO2. Following
virus adsorption, a solution of 2% methylcellulose (Sigma-M0512-250G) was diluted 1:1 in 5%
DMEM and warmed to room temperature. The methylcellulose-media mixture overlay was
added to the plate by adding 125 μL of overlay media to each well and returned to an incubator
with 37˚C, 5% CO2 for 24 hours. Plates were then fixed in a solution of 5% paraformaldehyde
(PFA) diluted in tissue culture grade 1X PBS, then washed in 1X PBS for 15 minutes. Foci
were visualized by an immunostaining protocol using anti-nucleocapsid protein antibody
(1D8) diluted 1:5000 to detect RVFV and anti-Gc protein antibody (4C12A1) diluted 1:5000 to
detect LACV with FFA staining buffer (1X PBS, 1mg/ml saponin (Sigma: 47036)) as a primary
detection antibody overnight at 4˚C. The anti-nucleocapsid protein antibody (1D8) was
obtained from Joel Dalrymple and Clarence J Peters (USAMRIID) via BEI resources. The secondary antibody consisted of goat anti-mouse conjugated horseradish peroxidase (Sigma: A7289) diluted 1:5,000 in FFA staining buffer and allowed to incubate for 2 hours at room temperature. Foci were visualized using KPL TrueBlue HRP substrate and allowed to develop for
10–15 minutes, or until blue foci are visible. The reaction was then quenched by washing with
Millipore water. RVFV ZH501 foci assays were measured within the BSL3 facility, while RVFV
MP12 and LACV viral foci were quantified with an automated ELISPOT machine (CTL universal S6) using the Immunospot software suite.

2.4. Antiviral compound efficacy assay
For RVFV (MP-12 and ZH501), Vero cells were plated at 3x105 cells per mL in a flat bottom
96 well plate. Twenty-four hours later they were infected with RVFV at a multiplicity of infection of 0.005. Compound was added and plates were incubated for 1 hour at 37˚C and then
cells were overlayed with methylcellulose. After 24 hours plates were fixed, RVFV infectious
foci were stained and quantified as described for the FFA above. Data is normalized to PBS,
using the average number of foci in each individual assay and presented as Focus Forming
Units (FFU). All assays required the range of foci to be 70–90 foci per control well for the assay
to pass quality control.
For RVFV (MP-12)- A549 cells, a human lung epithelial cell line, were plated at 3x105 cells
per mL in 96 well plates and incubated at 37˚C for 24 hours. Cells were then infected with
RVFV strain MP-12 at a multiplicity of infection of 0.005. Plates were incubated for 1 hour at
37˚C and then cells were overlayed with methylcellulose. After 24 hours plates were fixed,
RVFV infectious foci were stained and quantified as described for the FFA above.
For LACV (original), Vero cells were plated at 2x105 cells per mL in a flat bottom 96 well
plate. Twenty-four hours later they were infected with LACV at a multiplicity of infection of
0.01. Compound was added and plates were incubated for 1 hour at 37˚C and then cells were
overlayed with methylcellulose. After 24 hours plates were fixed, LACV infectious foci were
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stained using the murine anti-LACV Gc antibody, detected with an anti-mouse HRP secondary antibody and quantified as described for the FFA above.
For Zika virus (ZIKV) we have used our previously validated assay [44, 45], briefly Vero
cells were plated at 4x105 cells per mL in a flat bottom 96 well plate. Twenty-four hours later
they were infected with ZIKV at a multiplicity of infection of 0.01. Compound was added and
plates were incubated for 1 hour at 37˚C and then cells were overlayed with methylcellulose.
After 48 hours plates were fixed, ZIKV infectious foci were stained using the ZIKV cross-reactive antibody (4G2), detected with an anti-mouse HRP secondary antibody and quantified as
described for the FFA above.
Fifty percent effective concentrations (EC50) for key hits were determined by screening for
suppression of viral growth using an eight point, 2.5-fold dilution series of the compounds
starting at 100 μM. EC50 values were calculated by non-linear curve fitting in GraphPad Prism
v8.

2.5. Compound cytotoxicity
Initial compound cytotoxicity was estimated in Vero cells in the primary antiviral compound
experiments by staining the virally infected, compound treated cells with crystal violet after
viral foci had been quantified. After cells were stained with crystal violet wells were washed 2x
with water. The crystal violet dye was then extracted using 50% ethanol and absorbance was
measured at 570nm in an ELISA plate reader. Estimated 50% cytotoxic concentration (CC50)
values were derived by non-linear curve fitting in GraphPad Prism of the four data points
derived from the primary screen.
Quantitative CC50 values were measured in two systems. Compound cytotoxicity in uninfected A549 cells was determined using the CytoTox-GloTM Cytotoxicity Assay (Promega)
according to the manufacturer’s instructions. Briefly, A549s were seeded at 3x105 cells per mL
in 96 well plates and incubated for 24 hours at 37˚C. An eight point, 3-fold dilution series of
compounds was added to the cellular monolayer starting with the highest concentration,
600 μM, in addition to DMSO and PBS as controls. Plates were incubated for 48 hours at
37˚C, then the AAF-Glo reagent was added to the cells for 15 minutes and luminescence was
measured to determine the number of dead cells. Lysis buffer was added next for 15 minutes,
then luminescence was measured to determine the total cell number. The dead cell number
was then subtracted from the total cell number to generate the viable cell number.
Second, cytotoxicity was measured in the HepG2-derived hepatoblastoma cell line,
HepDES19 [46]. Cells were treated with a range of compound concentrations in a final DMSO
concentration of 1% for three days and mitochondrial function was measured by MTS assays
as described [47]. CC50 values were then calculated by non-linear curve fitting in GraphPad
Prism v8.

2.6. RNaseH inhibition reactions
Activity of human RNaseH was measured using a FRET assay in which the RNA:DNA heteroduplex was formed by annealing an 18 nucleotide-long RNA oligonucleotide with a fluorescein
label at the 3’ end to a complementary DNA oligonucleotide with an Iowa Black quencher at
the 5’ end. RNaseH activity cleaves the RNA, permitting the fluorescein to diffuse away from
the quencher, increasing fluorescence. The oligonucleotides employed were:
DNA: 5’-IABkFQ-AGC TCC CAG GCT CAG ATC-3’ (IABkFQ: Iowa Black quencher)
RNA: 5’- GAU CUG AGC CUG GGA GCU FAM-3’ (FAM: Fluorescein fluorophore).
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Recombinant human RNaseH 1 was purified from E. coli as described in [48]. Enzyme and
substrate (12.5 nM) were combined in 100 mM NaCl, 50 mM HEPES pH 8.0, 2 U RNase OUT
(ThermoFisher), and test compound in a final concentration of 1% DMSO. Reactions were
started by adding MgCl2 to 5 mM and incubating at 37˚C for 90 min. with detection of fluorescence every 2 min. in a plate reader. The initial rate was determined for each compound concentration, and IC50 values were determined from the reaction rates by non-linear curve
fitting in GraphPad Prism.

3. Results
3.1. Development and validation of a live virus bunyavirus antiviral
compound efficacy assay
Based on our previous work optimizing focus forming assays (FFAs) for Zika virus (ZIKV)
and SARS-CoV-2, [45, 49, 50] we developed an antiviral compound efficacy assay for RVFV
and LACV. We chose to develop an FFA because it is a high-throughput cell-based assay that
can capture a range of information about viral growth and replication, such as number of
infection foci and foci morphology. Virally induced foci data serve as critical information for
the development of antiviral compounds. To establish and validate the assay, we identified an
appropriate cell line, defined the primary antibodies capable of detecting viral antigen, and
determined an optimal cell concentration for seeding the wells of 96 well plates. Previous work
from a number of laboratories demonstrated that Vero E6 cells, a non-human primate African
green monkey kidney epithelial cell line, are highly sensitive to RVFV infection and widely
available [51].
To identify an appropriate primary antibody to detect viral antigen, we stained a serial dilution of virally infected Vero E6 cells. We evaluated 5 total monoclonal antibodies (mAbs), with
2 antibodies recognizing the Gc glycoprotein (4B6, 3D11), 2 antibodies recognizing the Gn
glycoprotein (7B6, 3C10), and one antibody recognizing the nucleocapsid protein (1D8) from
the Joel M. Dalrymple and Clarence J. Peters (USAMRIID antibody collection) (Fig 1A). The
murine anti-flavivirus mAb 4G2 was used as a negative control. The mAb 1D8 had the best signal to noise ratio and was thus used throughout the rest of these studies.
In order for RVFV to form distinct foci and for the assay to have the highest level of sensitivity, it is critical to plate cells at an optimal density. We examined the impact of cell density
on foci formation by plating identical dilutions of RVFV virus stocks on 96-well plates seeded
with differing numbers of E6 cells (7.5 × 104, 1.5 × 105 or 3 × 105 cells/mL). At these concentrations, the monolayers were ~70, 80 and 90 percent confluent, respectively, and the same virus
dilution resulted in 1 × 103 FFU/mL of RVFV MP-12. We observed the highest sensitivity
when either 1.5 × 105 or 3 × 105 cells/mL were seeded in comparison to 7.5 × 104 cells/mL
(Fig 1B). We have previously tested higher cell densities for FFAs measuring flavivirus and
coronavirus replication, and we have noted that cell concentrations higher than 3 × 105 cells/
mL results in an overly confluent monolayer with more cells than can adhere to the wells,
which can lead to highly variable viral titer information [45].
To validate the assay design, we completed an antiviral compound inhibition assay by plating Vero E6 cells at 3x105 cells/ml in a 96 well flat bottom plate. These wells were infected with
sufficient virus to form ~70–80 foci per well, and cells were treated with serial dilutions of ribavirin or β-D-N4-Hydroxycytidine N4-Hydroxycytidine (NHC/EIDD-1931) starting at 100μM
as positive controls. Further, additional wells served as negative controls by being treated with
100μM DMSO as a vehicle control or PBS. The ratio of foci forming units (FFU) in comparison to PBS was measured and the effective concentration 50 (EC50) was calculated. Ribavirin
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Fig 1. Development and validation of RVFV antiviral screen. A. Identification of optimal mAb for the detection of
RVFV by mAb staining of a serial dilution of RVFV strain MP-12 in an FFA. B. Impact of cell number on the
sensitivity of antiviral compound screen. C. Evaluation of the sensitivity of the antiviral compound screen based upon
the evaluation of ribavirin and β-D-N4-Hydroxycytidine N4-Hydroxycytidine (NHC/EIDD-1931), a known antiviral
for RVFV. Data is presented as focus forming units. These data are the cumulation of three independent experiments
with technical duplicates.
https://doi.org/10.1371/journal.pone.0274266.g001
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had an EC50 of 22.0 μM, similar to work by other groups [52, 53], while the EC50 value for
NHC was 5.16 μM (Fig 1C).

3.2. Primary screening for antiviral activity
Primary screens were conducted that evaluated 397 compounds either with known metal-chelating motifs or motifs similar to metal-chelating ones. The most common chemotype among
the compounds screened was the troponoids (tropones, tropolones (TRP), thiotropolones
(TTP), and α-hydroxytropolones (αHTs)), but the compound set also included a wide range of
other chemotypes such as the N-hydroxypyridinediones (HPD), flavonoids, N-hydroxynapthyridinones, dihydronapthalenes (DHN), dioxobutanoic acids, hydroxyxanthanones,
thienopyrimidinones, pyridinepiperazinthieonpyrimidins, N-biphenyltrihydroxybenzamides,
and aminocyanothiophenes. Almost half of the compounds screened were αHTs as the library
from which they were drawn was assembled in support of anti-HBV ribonuclease H antiviral
development and the αHTs are a leading chemotype in that effort [38, 54, 55].
To screen these compounds for antiviral activity, FFAs were used. Briefly, cells were
infected with RVFV MP-12, treated with 60, 20, 6.7, or 2.2 μM of compound, and the number
of RVFV foci was determined 24 hours later. Antiviral efficacy was calculated as an estimated
50% effective concentration (EC50) from the number of RVFV foci detected in comparison to
vehicle control (S1 Table). Following detection of the RVFV foci, cytotoxicity concentrations
(CC50) were estimated by qualitatively assessing monolayer integrity by staining the cell monolayers with crystal violet and measuring the optical density of crystal violet staining, which is
proportional to the number of viable cells. Screening hits were defined as compounds that i)
had an estimated EC50 determined from the four-point screening assay of <20 μM and ii) by
measuring monolayer integrity using crystal violet, as commonly done for cell-based
bioassays.
Forty-seven screening hits were identified (S1 Table). Thirty-nine of 174 troponoids
screened (22%) were hits, with 34 of them being αHTs, three being TRPs, and two being TTPs.
In contrast, only eight of 223 non-troponoids (3.6%) were hits. Seven of these eight hits were
HPDs. The hit rate among the 24 HPDs screened (29%) was similar to that of the αHTs. The
remaining screening hit was a DHN.

3.3. Quantification of antiviral activity against RVFV
Based upon the activity of the primary screen of αHTs and HPDs and because their antiviral
activity against RVFV is novel, we defined the dose-response curve for 25 αHTs, 4 HPDs, and
6 additional compounds selected to broaden the chemical diversity. This also served to spotcheck compounds with poor estimated EC50 values. In these studies, Vero cells were treated
with 8 different concentrations ranging from 60 to 0.024 μM at the time of infection and their
ability to prevent virus replication was measured by comparing the number of viral infection
foci to wells treated with vehicle control. EC50 ranged from 1.2 to 40.8 μM (Table 1), with 21 of
the top 30 compounds being αHTs. Interestingly, two closely related compounds AG-II-18-P
(308), a thiophene substituted αHT and the closely related furan counterpart AG-I-183-P
(309), had an EC50 of 1.2 μM and 1.6 μM respectively, and were the two best compounds
identified.
To better understand potential cellular cytotoxicity in the context of infection, crystal violet
staining of the cell monolayers was quantified by absorbance and CC50 values were calculated
after foci were counted. The CC50 ranged from 44 to >120 μM in Vero cells, with 24 compounds having a CC50 of >120 μM. Second, cytotoxicity was assessed in the HepG2 derivative
HepDES19 [46] to model longer-duration compound exposure in hepatocytes. Cells were
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Table 1. Top antiviral hits.
Name 1

Compound number

Chemotype 2

EC50 (μM)

CC50 (μM)3

SI

Chemist

α-Hydroxytropolones
308

AG-II-18-P

αHT

1.2

111

92

Murelli

309

AG-I-183-P

αHT

1.6

>120

75

Murelli

362

DS-I-69

αHT

2.5

80

32

Murelli

694

NBA-I-127 Bis

αHT

3.7

>120

32

Murelli

359

AG-II-108-C

αHT

5.1

>120

24

Murelli

696

NBA-I-128 Bis

αHT

6.0

118

20

Murelli

1017

AL-23

αHT

8.0

>120

15

Murelli

867

DS-1-124

αHT

8.7

>120

14

Murelli

702

NBA-I-159 Mono

αHT

8.8

>120

14

Murelli

1039

AB-3-45

αHT

8.9

>120

13

Murelli

336

YA-I-78

αHT

9.0

70

8

Murelli

330

NBA-I-14

αHT

10.4

>120

12

Murelli

698

NBA-I-150

αHT

11.7

>120

10

Murelli

311

AG-II-3-P

αHT

11.8

115

10

Murelli

210

MolMoll 19617

αHT

11.8

>120

10

Purchased

390

AB-2-70

αHT

11.9

>120

10

Murelli

838

NBA-I-130

αHT

12.7

>120

9

Murelli

704

NBA-I-160

αHT

14.3

>120

8

Murelli
Murelli

331

NBA-I-31

αHT

15.8

80.4

5

703

NBA-I-159 Bis

αHT

16.1

>120

7

Murelli

539

AB-2-91

αHT

18.6

71

4

Murelli

840

NBA-I-155-Mono

αHT

31.6

>120

4

Murelli

320

NBA-I-13

αHT

34.0

>120

4

Murelli

335

DH-2-60

αHT

40.8

>120

3

Murelli

TTP

6.3

>120

19

Elgendy

TTP

6.2

>120

19

Elgendy

Thiotropolones
680

BE1105

686

BE1111

Tropolones
341

Specs AP-355/40802214

TRP

25.2

>120

5

Purchased

340

Specs AP-355/40633884

TRP

27.3

70

4

Purchased

342

Specs AP-355/40633885

TRP

55.5

>120

2

Purchased

N-Hydroxypyridinediones
670

ZEV-V7

HPD

14.0

>120

9

Zoidis

668

ZEV-V5

HPD

19.2

>120

6

Zoidis

518

ZEV-V3

HPD

19.5

>120

6

Zoidis

515

ZEV-E2

HPD

24.3

>120

5

Zoidis

327

Aldrich Select CNC_ID 444085867

39.7

44

1.1

Purchased

Dihydronapthalene
DHN
Nucleoside Analogue
EIDD-1931

1
2

β-D-N4-HydroxycytidineN4-Hydroxycytidine

Nuc

5.2

>120

23

Purchased

Ribavirin

Nuc

22.0

>120

5

Purchased

Chemist’s name, common name, or vendor catalog number.
αHT, α-Hydroxytropolone; TRP, tropolone; TTP, thiotropolone; DHN, dihydronapthalene; HPD, N-Hydroxypyridinedione; FLV, flavenoid; DOB, dioxobutanoic

acid; HXT, hydroxyxanthanone; TPD, thieopyrimidinone; ACT, aminocyanothiophene.
3

Values of 120 indicate the data were at or above the upper limit of quantification in the assay.

https://doi.org/10.1371/journal.pone.0274266.t001
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Table 2. EC50 against RVFV replication.
A549

Vero

Compound number

Compound name

Chemotype

EC50, μM

CC50 μM

SI

EC50, μM

CC50 μM

SI

309

AG-I-183-P

αHT

5.9

98.1

16.8

1.6

>120

75.0

686

BE1111

TTP

7.9

67.6

8.6

6.3

>120

19

308

AG-II-18-P

αHT

8.4

119.0

14.2

1.2

>120

100.0

390

AB-2-70

αHT

9.4

224.2

23.9

11.9

>120

10.1

680

BE1105

TTP

11.6

>240

20.7

6.3

>120

19.0

670

ZEV-V7

HPD

15.3

>240

15.7

14

>120

8.6

840

NBA-I-155-Mono

αHT

15.4

141.6

9.2

31.6

>120

3.8

1039

AB-3-45

αHT

15.5

>240

15.5

8.9

>120

13.5

518

ZEV-V3

HPD

17.2

16.5

1.0

20.0

>120

6.0

331

NBA-I-31

αHT

17.7

>240

13.6

15.8

80.4

5.0

327

Aldrich Select CNC_ID 444085867

DHN

19.6

27.5

1.4

39.7

42.9

1.1

704

NBA-I-160

αHT

20.0

43.0

2.2

14.3

>120

8.4

867

DS-1-124

αHT

33.0

>240

7.3

8.7

>120

13.8

668

ZEV-V5

HPD

35.7

82.0

2.3

19.2

>120

6.3

330

NBA-I-14

αHT

42.6

>240

5.6

10.4

>120

11.5

320

NBA-I-13

αHT

90.3

154.1

1.7

33.96

>120

3.5

517

ZEV-V2

HPD

95.8

71.8

0.7

>120

>120

-

515

ZEV-E2

HPD

>120

93.6

0.6

24.3

>120

4.9

335

DH-2-60

αHT

>120

96.2

0.3

40.8

>120

2.9

https://doi.org/10.1371/journal.pone.0274266.t002

treated with a range of compound concentrations for three days and mitochondrial function
was measured using MTS assays. CC50 values ranged 1.8 to >100 μM in the hepatoblastoma
cells (S2 Table).
To validate compound efficacy and cytotoxicity, we completed additional dose response
curve experiments in A549 cells (Table 2 and Fig 2). We selected A549 cells, a human alveolar
basal epithelial cell line, for two reasons, the potential for respiratory exposure of humans via
aerosol or droplets and the epithelial nature of A549s because of the evidence that natural
infection of RVFV leads to infection of epithelial cells within the kidney, liver, and spleen [5,
56, 57]. There was a concordance for the majority of compounds between the EC50 value
defined in Vero cells and the EC50 concentration defined in A549 cells. The values from the
corresponding compounds in Vero cells is provided next to the data for A549s. In A549 cells,
both compound AG-II-18-P (308), a thiophene substituted αHT, and its furan counterpart
(309) had the lowest EC50 values of 8.4 and 5.9 μM, respectively. To quantify cytotoxicity independent of viral infection, cellular toxicity was quantified by measuring intracellular protease
release. In this manner, we were able to quantify cytotoxicity in the same cell lines which were
used to determine efficacy. In these assays, A549 cells were cultured and plated as for the efficacy assays, and cells were incubated with compound for two days and cell viability measured.
For the αHTs, CC50 values ranged from 43 to >240 μM, and they ranged from 16.5
to > 240 μM for the HPDs.

3.4. Efficacy of compounds against wild type RVFV and LACV
In order to determine efficacy for wild type isolates of RVFV, we measured the efficacy of the
αHT AG-II-18-P (308) and the nucleoside analogues NHC and ribavirin as a positive control
against the highly pathogenic strain ZH501 in Vero cells (Fig 3A). Both NHC and ribavirin are
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Fig 2. In vitro dose-response and cytotoxicity of compounds against RVFV (MP12). A549 cells were infected with RVFV MP12 then treated with
decreasing concentrations of compound. The reduction in virus concentration was measured by FFA at twenty-four hours post infection. Data is
representative of three individual experiments with two biological replicates. Error bars represent standard deviation.
https://doi.org/10.1371/journal.pone.0274266.g002
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Fig 3. Antiviral effect of compounds on bunyavirus replication. Vero cells were infected with either RVFV ZH501 (A) or LACV (B) then treated with
decreasing concentrations of antiviral compound. Viral growth was measured by FFA. Data represents three independent experiments completed with
biological replicates. Error bars represent standard deviation.
https://doi.org/10.1371/journal.pone.0274266.g003

small molecule inhibitors, with ribavirin having demonstrated activity against RVFV and
NHC a nucleoside analog with activity against a broad array of viruses. The assay design is
identical to Fig 1, with the exception that foci were measured at 18 hours post infection
because of the increased rate of replication. In this assay, compound 308 had an EC50 of
54 μM, while NHC and ribavirin had EC50 values of 30.5 and 73.6 μM. Prior investigations of
ribavirin restriction of RVFV has demonstrated similar results in Vero cells, showing the validity of the assay, and acting as a reference point for the novel compounds identified [53].
To determine if the metal chelating compounds including the αHTs AG-II-18-P (308),
AG-I-183-P (309) and 16 related compounds were specific to RVFV or would have a broader
activity, we investigated efficacy of these compounds against the bunyavirus LACV, as well as
an unrelated flavivirus, ZIKV in Vero E6 cells. All three viral pathogens require viral metalloproteases for viral replication, while RVFV and LACV also encode a viral endonuclease used
for cap-snatching [10–12, 58]. We observed a dose-dependent decrease in viral titers in the
antiviral efficacy assays, with 6 of the 18 metal chelating compounds against LACV virus
resulting in EC50’s ranging between 12.7 and 89.15 μM, while the nucleoside analogue βD-N4-Hydroxycytidine had an EC50 of 3.6 μM (Fig 3B and Table 3). Of the 6 compounds that
had activity against LACV, only 2 had activity against ZIKV. The αHT compound 704 and the
TTP compound 680 had EC50’s of 23.0 and 19.5 μM respectively, with the nucleoside analogue
β-D-N4-Hydroxycytidine having a EC50 of 1.7 μM. The ability of a subset of compounds to
inhibit the growth and replication of both RVFV and LACV speaks to the potential of these
metal chelating compounds to be developed as potential bunyaviridae therapeutics, or potentially as phlebovirus (RVFV)-or orthobunyavirus (LACV)-specific antivirals.

3.5. Selective indexes
Selectivity indexes (SI or CC50/EC50) were calculated for all compounds with EC50 values
based on cytotoxicity in both Vero cells after one day compound treatment and in A549 cells
after two days of treatment. SIs ranged from <1 to 402 in Vero cells (Table 1 and S2 Table)
and <1 to 23.9 in A549 cells (Table 2). Confirmed hits were defined as compounds with
SIs > 5 in Vero cells (n = 34) because this indicates that the reduction in RVFV foci was not a
result of non-specific killing of the Vero cells in which the assays were completed (Table 1).
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Table 3. EC50 against LACV and ZIKV replication.
Compound number

Compound name

Chemotype

LACV EC50, μM

ZIKV EC50, μM

308

AG-II-18-P

αHT

15.1

>120

309

AG-I-183-P

αHT

14.6

>120

320

NBA-I-13

αHT

>120

>120
>120

327

Aldrich Select CNC_ID 444085867

DHN

12.7

330

NBA-I-14

αHT

>120

32.7

335

DH-2-60

αHT

>120

>120

390

AB-2-70

αHT

>120

>120

515

ZEV-E2

HPD

>120

>120

517

ZEV-V2

HPD

>120

>120

518

ZEV-V3

HPD

>120

>120

668

ZEV-V5

HPD

>120

>120

670

ZEV-V7

HPD

>120

>120

680

BE1105

TTP

31.3

23

686

BE1111

TTP

45.4

>120

704

NBA-I-160

αHT

89.15

19.5

840

NBA-I-155-Mono

αHT

>120

>120

867

DS-1-124

αHT

>120

>120

1039

AB-3-45

αHT

>120

>120

NHC

β-D-N4-Hydroxycytidine

NUC

3.6

1.74

https://doi.org/10.1371/journal.pone.0274266.t003

Structures of all compounds in Tables 1 and 2 are in S2 Data, and structures of all confirmed
hits are in S3 Data.

4. Discussion
Most primary hit compounds against RVFV were either αHTs or HPDs, but TRP, TTP, and
DHN hits were also found. This distribution of hits is partially due to sampling bias owing to
the disproportionate number of αHTs in the compound collection screened. Sampling bias,
however, does not fully explain the hit distribution because only a minority of the αHTs
screened were active, and because there were many chemotypes in the compound collection
where hits were not found. These included dioxobutanoic acids, hydroxyxanthanones, thienopyrimidinones, pyridinepiperazinthieonpyrimidins, N-biphenyltrihydroxybenzamides, and
aminocyanothiophenes. EC50 values of the 62 compounds for which quantitative data were
obtained ranged from 0.1 to >120 μM (S1 and S2 Tables). Selective indexes for these compounds in Vero cells in which the screening was conducted ranged from 1.1 to 1200. Twentyeight compounds were confirmed hits based upon their selective index (SIs > 5 in Vero cells,
7.5% of the compounds screened) indicating that they were due to bona fide inhibition of
RVFV rather than secondary effects of cytotoxicity. However, the increased CC50 values in the
A549 (16.5 to >240 μM) and HepDES19 cells (<1 to 48 μM) indicate that compounds active
against RVFV replication can have cytotoxicity in human lung and liver-derived cells, which
must be addressed during subsequent hit-to-lead medicinal chemistry campaigns. One avenue
for reducing cytotoxicity, at least for the αHTs, may be to reduce the lipophilicity and number
of aromatic rings in the molecules because these parameters correlate with αHT toxicity [38].
RVFV infections proceed rapidly in vivo, so optimizing these hits to achieve toxicity profiles
suitable for a one- to two-week treatment regimen in RVFV-infected patients or animals will
likely be enough to yield usable drugs.

PLOS ONE | https://doi.org/10.1371/journal.pone.0274266 September 16, 2022

13 / 20

PLOS ONE

Small compound efficacy against Bunyavirales

Identification of primary screen hits among the αHT, HPD, TRP, TTP, and DHN chemotypes indicates that a range of compounds can inhibit RVFV replication, but the lack of hits
among the other chemotypes screened implies that there is specificity to RVFV inhibition
(Fig 4). This is further supported by the efficacy of a subset of αHT class of compounds against
LACV, with two of the compounds (308, 309) having activity against LACV, but not the unrelated flavivirus, Zika virus. The potential for specific inhibition of RVFV was confirmed by the
wide range of inhibition patterns observed during counter-screening (S2 Table). For example,
compound 362 had an EC50 of 2.6 μM vs. RVFV, an IC50 against human ribonuclease H1 of
212 μM, was inactive against E. coli growth, and was only modestly effective against the pathogenic fungus C. neoformans (minimum 80% inhibitory concentration (MIC80) = 24 μM). This
indicates that although these chemotypes which can bid to the active sites of metalloenzymes
and can have broad anti-microbial activity, individual compounds can be selective through
specific interactions with their various targets (reviewed in [59]).
The 174 troponoids (αHTs, TRPs, TTPs) evaluated yielded 28 confirmed hits with TI
values � 5 (Table 1). Inhibition of RFVF by tropolones appears to require an intact metal ion
chelating trident on the compound, which implies an interaction with two closely-spaced divalent cations on the target molecule due to the compounds’ known mechanisms of metal chelation (Fig 4a) [59]. For example, while the tropolones β- and γ-thujaplicin were inactive against
the virus at concentrations upwards of 120 μM, the αHT β–thujaplicinol (46) was active, with
an EC50 of 13.8 μM (Fig 2A). These trends extended to additional αHTs, of which 11 different
molecules had EC50 values under 10 μM (Table 1), the most potent of which had an EC50 of
1.2 μM (308), (S3 Data). These more potent molecules had a broad range of appendages (Fig
4B), such as ketone (308, 309, 359, 362), amide (867, 1017, 1039), mono- (702) and bis (694,
696) thioethers, sulfoxide (336), and included a 3,7-dihydroxytropolone (362). Thus, there is
tolerance to a variety of functional groups (Fig 4c). Apart from the αHTs, four additional tropolones had measurable EC50 values (TRPs 340, 341, 342 and 359, EC50 = 5.1–55.5 μM), each
of which had a carbonyl appendage α to the tropolone oxygens that could provide an alternative third cation contact point. However, only 341 had an EC50 under 10 mM (S2 Data).
Intriguingly, both acylated thiotropolones (680, 686) had sub-mM activity despite the lack of
any tridentate cation binding motif. It seems possible that these thioester linkages could
undergo cleavage in the cell, and that the active component in both instances is the free thiotropolone, as has been postulated previously for their potent anti-Cryptococcus neoformans
activity [37].
Seven HPD primary hits were found among the 24 HPDs screened. Four of these were confirmed hits, 515, 518, 668, and 670, with EC50 values ranging from 14.0–24.3 μM (Fig 2). This
is insufficient to generate a meaningful structure-activity relationship, but trends can be
inferred. The oxygen trident of the HPD scaffold is essential for its activity, as the loss of any
one of these oxygens results in inactive compounds. In each case it is presumed based on data
with other HPDs against HBV [47] that strong ionic interactions, along with charge-assisted
hydrogen bonds potentially anchor the chelator moiety of HPDs (N-Hydroxyimide group) to
a cellular or viral metalloenzyme ensemble comprised of the two positively charged Mg++ ions.
Lastly, aromatic substitutions at the imine nitrogen are tolerated that carry modifications
including halogen electron withdrawing groups and an alkyl electron donating group.
The mechanism(s) of action of these RVFV inhibitors are unknown and could involve inhibition of viral and/or cellular proteins. However, inhibiting one or more mono- or di-metalloenzymes needed for viral replication by chelating their active site cations is a potential
mechanism. The rationale for implicating metal chelation comes from the compound structures and their known activities against HIV and HBV [16–18]. The αHTs and HPDs have
metal chelating tridents suitable for binding to the Mg++ ions in di-metalloenzyme active sites,
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Fig 4. Representative structures of RFVF inhibitors. (A) Inactive and active troponoid natural products, illustrating preference for oxygen triad,
along with common nuclease inhibition mode for αHTs. (B) Synthetic αHTs with activity under 10 μM against RVFV, demonstrating broad
substitution tolerance. (C) Representative examples of alternative scaffolds with activity against RFVF.
https://doi.org/10.1371/journal.pone.0274266.g004

and the αHTs are known to work by this mechanism against the HIV ribonuclease H and/or
integrase [17, 21]. However, the failure of many compounds with known ability to inhibit divalent cation containing metalloenzymes (~70% of the αHTs did not inhibit RVFV growth) indicates that metal chelation by itself is insufficient, presumably because additional compound:
target interactions are needed to provide sufficient binding affinity to inhibit viral replication.
One potential target for these inhibitors is the RVFV L protein, where either the viral RNAdependent RNA polymerase (RdRp) activity or the cap-snatching endonuclease activity of the
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viral L protein could be affected [32, 60]. This is because both are di-metalloenzymes that catalyze a reaction required for viral replication.

5. Conclusions
Screening for RVFV replication inhibitors among compounds selected for their similarity to
inhibitors of viral nucleases identified 47 novel RVFV inhibitors. The frequent efficacy of the
αHT and HPD compounds screened against RVFV replication indicates that these two scaffolds are promising candidates for optimization into anti-RVFV drugs that target metalloenzymes for use against human and/or veterinary infections. Cytotoxicity was observed in
human hepatoblastoma cells, indicating that identifying and mitigating the causes of cytotoxicity will be key to optimizing these hits. The conserved features of viral replication among
Bunyavirales, and the activity of these compounds against RVFV and a subset of these compounds having activity against LACV implies that these hits hold potential for development
into treatments for related pathogens, including Hantaan virus, severe fever with thrombocytopenia syndrome virus, and Crimean-Congo hemorrhagic fever virus.
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